麻豆传媒

• share
• favorite_border

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published results of an expansive global review answering a basic scientific question, 鈥淗ow do you describe a 鈥榬are disease?鈥欌�� in 鈥淩are Disease Terminology and Definitions.鈥�

• share
• favorite_border

ISPOR published a new Task Force Report, 鈥淐linical Outcome Assessments (COAs): A Conceptual Foundation 鈥� Report of the ISPOR Clinical Outcomes Assessment Emerging Good Practices Task Force,鈥� in Value in Health.

• share
• favorite_border

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a new Task Force Report, 鈥淢ultiple Criteria Decision Analysis for Health Care Decision Making鈥擜n Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force,鈥� in the January/February 2016 issue of Value in Health (Volume 19, Issue 1).

• share
• favorite_border

ISPOR published a new Task Force Report, 鈥淢ultiple Criteria Decision Analysis for Health Care Decision Making鈥擡merging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force, 鈥� in the March/April 2016 issue of Value in Health.

• share
• favorite_border

ISPOR has published its third Good Research Practices Task Force Report on preference-based methods that measure patient and other stakeholder preferences. The report appears in the June 2016 issue (Volume 19, Issue 4) of Value in Health.

• share
• favorite_border

ISPOR announced today the publication of an empirical study demonstrating that current Medicaid policies restricting hepatitis C treatment to patients with advanced disease are more costly and less effective than unrestricted, full-access strategies.

• share
• favorite_border

ISPOR announced the publication of a study comparing the metrics obtained from profile-case best-worst scaling (BWS) with those from a discrete choice experiment (DCE) with respect to hip replacement surgery. The study was published in the June 2016 issue of Value in Health.

• share
• favorite_border

ISPOR announced today the publication of a series of articles suggesting that the application of cost-effectiveness analysis for health care decision making in the US may be approaching critical mass. This special themed section was published in the July/August 2016 in Value in Health.

• share
• favorite_border

ISPOR's Medical Devices and Diagnostics Special Interest Group report, 鈥淗ealth Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations,鈥� was published in the July/August 2016 issue (Volume 19, Issue 5) of Value in Health.

• share
• favorite_border

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has published a new report, 鈥淓stimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report,鈥� in the September/October 2016 issue of Value in Health.